Research programme: gene therapies - Audentes Therapeutics

Drug Profile

Research programme: gene therapies - Audentes Therapeutics

Alternative Names: AAV-CASQ2 gene therapy - Audentes; AAV-MTM1 (AT001); AT 132; AT 307; AT 982; AT-001 - Audentes/REGENXBIO; AT-002 - Audentes/REGENXBIO; AT-003 - Audentes/REGENXBIO; XLMTM gene therapy (AT001) - Audentes/Genethon

Latest Information Update: 14 Mar 2017

Price : $50

At a glance

  • Originator Audentes Therapeutics; Genethon
  • Class Gene therapies
  • Mechanism of Action Alpha glucosidase expression stimulants; Gene transference; Myotubularin expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Musculoskeletal disorders
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Glycogen storage disease type II; Musculoskeletal disorders; Ventricular tachycardia

Most Recent Events

  • 09 Mar 2017 Audentes Therapeutics plans to file an IND application for AT 307 for Musculoskeletal disorders (related catecholaminergic polymorphic ventricular tachycardia)
  • 09 Mar 2017 Audentes Therapeutics files an IND application with the FDA in USA for Musculoskeletal disorders (X-linked myotubular myopathy)
  • 12 Nov 2016 Audented Therapeutics plans to file an IND application with the US FDA for Glycogen storage disease type II in the fourth quarter of 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top